Research & Clinical Summary

The goals of the DePaolo Lab are to explore how intestinal perturbations caused by genetics and/or environmental factors (e.g., diet, infection, pollution) alter the microbial landscape of the intestine and to use this newly acquired knowledge to develop strategies and therapies to maintain or restore ecological harmony. To accomplish these goals the DePaolo Lab utilizes an integrated and multidisciplinary approach that incorporates both clinical human samples with relevant animal models of disease and pairs –omics data with novel assays to define actual biological function. Through careful analysis and holistic approaches the DePaolo Lab hopes to define new pathways, identify new targets and gain mechanistic insight into the relationship between the environment, human genes and the microbiome.

Interests: Metabolism, Metabolome, Tissue Injury & Regeneration

Publications

The following publications were retrieved from PubMed:

Sugiura Y, Kamdar K, Khakpour S, Young G, Karpus WJ, DePaolo RW,
“TLR1-induced chemokine production is critical for mucosal immunity against Yersinia enterocolitica.”
Mucosal immunology 6.6 (2013 Nov): 1101-9.

Michail S, Bultron G, Depaolo RW,
“Genetic variants associated with Crohn’s disease.”
The application of clinical genetics 6. (2013): 25-32.

Nguyen V, Pearson K, Kim JH, Kamdar K, DePaolo RW,
“Retinoic acid can exacerbate T cell intrinsic TLR2 activation to promote tolerance.”
PloS one 10.3 (2015): e0118875.

Kamdar K, Khakpour S, Chen J, Leone V, Brulc J, Mangatu T, Antonopoulos DA, Chang EB, Kahn SA, Kirschner BS, Young G, DePaolo RW,
“Genetic and Metabolic Signals during Acute Enteric Bacterial Infection Alter the Microbiota and Drive Progression to Chronic Inflammatory Disease.”
Cell host & microbe 19.1 (2016 Jan 13): 21-31.

Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ,
“Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.”
Molecular cancer therapeutics 15.7 (2016 Jul): 1740-5.

Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ,
“Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.”
International journal of cancer 141.6 (2017 Sep 15): 1222-1230.